Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) is opposed to the Substitute for House Bill 4812 because the U.S. Food and Drug Administration (FDA) has not released guidance on how applicants can demonstrate interchangeability.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Disease Control and Prevention (CDC) for its work in developing strategies to address the growing opioid epidemic in the United States and for the opportunity to provide comments in response to the Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain (CDC-2015-0112).
The Academy of Managed Care Pharmacy (AMCP) is pleased to provide general comments and recommendations to the Call for Comments on Endorsement Consideration by PQA Members of a New Performance Measure: Adherence to Long-Acting Inhaled Bronchodilator Agents in COPD Patients.
